Advertisement
Canada markets closed
  • S&P/TSX

    22,639.57
    -174.18 (-0.76%)
     
  • S&P 500

    5,427.13
    -128.61 (-2.31%)
     
  • DOW

    39,853.87
    -504.22 (-1.25%)
     
  • CAD/USD

    0.7241
    -0.0017 (-0.24%)
     
  • CRUDE OIL

    77.46
    +0.50 (+0.65%)
     
  • Bitcoin CAD

    90,985.28
    +371.72 (+0.41%)
     
  • CMC Crypto 200

    1,351.84
    -14.06 (-1.03%)
     
  • GOLD FUTURES

    2,399.00
    -8.30 (-0.34%)
     
  • RUSSELL 2000

    2,195.37
    -47.89 (-2.13%)
     
  • 10-Yr Bond

    4.2860
    +0.0470 (+1.11%)
     
  • NASDAQ

    17,342.41
    -654.94 (-3.64%)
     
  • VOLATILITY

    18.04
    +3.32 (+22.54%)
     
  • FTSE

    8,153.69
    -13.68 (-0.17%)
     
  • NIKKEI 225

    39,154.85
    -439.54 (-1.11%)
     
  • CAD/EUR

    0.6678
    -0.0004 (-0.06%)
     

Gilead Sciences Stock: Bear vs. Bull

Gilead Sciences Stock: Bear vs. Bull

You may know of Gilead Sciences (NASDAQ: GILD) because of its blockbuster coronavirus treatment Veklury. In fact, the S&P 500 has outperformed Gilead over the past five years. Gilead has struggled to consistently deliver annual revenue growth ever since its hepatitis C portfolio's revenue reached a peak back in 2015.